May 2, 2017 09:23 AM EDT
R&D

Pfiz­er dumps a failed PhII Hunt­ing­ton’s drug in lat­est pipeline prun­ing

John Carroll

Editor & Founder

Pfiz­er used one of its foot­notes in the Q1 re­port to sweep out an ex­per­i­men­tal Hunt­ing­ton’s drug that failed re­cent­ly in a Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times